Consequently, to gain broader insights into the molecular basis for this IRF8-dependent tumor growth advantage, we performed preliminary microarray studies using the IRF8-expressing/IRF8-deficient CMS4 mouse isogenic tumor pair. Here, IRF8 is linked to neoplasm.